bioRxiv Science⌕ Search

Biology subjects

Showers, W.

Publications and source records attributed to Showers, W..

3 recordsLinked to original sources

scExploreR: a flexible platform for democratized analysis of multimodal single-cell data by non-programmers

Single-cell sequencing has revolutionized biomedical research by uncovering cellular heterogeneity in disease mechanisms, with significant potential for advancing personalized medicine. However, participation in single-cell data analysis is limited by the programming experience required to access data. Several existing browsers allow the interrogation of single-cell data through a point-and-click interface accessible to non-programmers, but many of these browsers are limited in the depth of analysis that can be performed, or the flexibility of input data formats accepted. Thus, programming experience is still required for comprehensive data analysis. We developed scExploreR to address these limitations and extend the range of analysis tasks that can be performed by non-programmers. scExploreR is implemented as a packaged R Shiny app that can be run locally or easily deployed for multiple users on a server. scExploreR offers extensive customization options for plots, allowing users to generate publication quality figures. Leveraging our SCUBA package, scExploreR seamlessly handles multimodal data, providing identical plotting capabilities regardless of input format. By empowering researchers to directly explore and analyze single-cell data, scExploreR bridges communication gaps between biological and computational scientists, streamlining insight generation.

bioinformatics↗

STAT3 modulates mitochondrial function and plays a critical role in the survival of leukemic stem cells

Signal transducer and activator of transcription 3 (STAT3) is a well-described transcription factor that mediates oxidative phosphorylation and glutamine uptake in bulk acute myeloid leukemia (AML) cells and leukemic stem cells (LSCs). STAT3 has also been shown to translocate to the mitochondria in AML cells, particularly when phosphorylated at the serine 727 (pSTAT3 S727) residue. Inhibition of STAT3 results in impaired mitochondrial function and decreased leukemia cell viability. We discovered a novel interaction of STAT3 with voltage-dependent anion channel 1 (VDAC1) in the mitochondria that provides a mechanism through which STAT3 modulates mitochondrial function and cell survival. Through VDAC1, STAT3 regulates calcium and oxidative phosphorylation in the mitochondria. STAT3 and VDAC1 inhibition also results in significantly reduced engraftment potential of LSCs, including primary samples resistant to venetoclax. These results implicate STAT3 as a therapeutic target in AML.

cancer biology↗

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

The BCL-2 inhibitor venetoclax has recently emerged as an important component of acute myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously unrecognized form of pathogenesis characterized by monocytic disease progression. We demonstrate that this form of disease arises from a fundamentally different type of leukemia stem cell (LSC), which we designate as monocytic LSC (m-LSC), that is developmentally and clinically distinct from the more well-described primitive LSC (p-LSC). The m-LSC is distinguished by a unique immunophenotype (CD34-, CD4+, CD11b-, CD14-, CD36-), unique transcriptional state, reliance on purine/pyrimidine metabolism, and selective sensitivity to cladribine. Critically, in some instances m-LSC and p-LSC subtypes can co-reside in the same AML patient and simultaneously contribute to overall tumor complexity. Thus, our findings demonstrate that LSC heterogeneity has direct clinical significance and highlights the need to distinguish and target m-LSCs as a means to improve clinical outcomes with venetoclax-based regimens. Statement of SignificanceThese studies identify and characterize a new type of human acute myeloid leukemia stem cell (LSC) that is responsible for monocytic disease progression in acute myeloid leukemia (AML) patients treated with venetoclax-based regimens. Our studies describe the phenotype, molecular properties, and drug sensitivities of this unique LSC subclass.

cancer biology↗